CYP17A1 and prostate carcinoma: Since PSA is regulatedby androgenic signaling, this implies that androgenic signaling remainsinvolved in CRPC progression.197 Therefore,androgen signaling remains central to prostate cancer pharmacology,leaving CYP17A1 inhibition as an important and attractive strategy.